Two drug discovery projects have been named recipients of the 2017 Biomedical Innovation Program awards. The awards program is a collaboration of the Oregon Clinical & Translational Research Institute, OHSU Technology Transfer & Business Development, and the Knight Cancer Institute. The awards provide funds, project management, and mentorship to facilitate the development of innovative technologies at OHSU and accelerate their translation to the marketplace. This track of funding supports drug discovery platforms and early stage therapeutic technology projects.
Monika Davare, Ph.D., an assistant professor of pediatrics in the OHSU School of Medicine’s Division of Hematology and Oncology, received an award to develop a ‘hit to lead’ compound as a therapeutic agent to treat Ewing’s sarcoma and subsets of hematological malignancies.
Professor Beth Habecker, Ph.D., and Associate Professor Michael Cohen, Ph.D., both from the OHSU Department of Physiology and Pharmacology, were awarded funding to develop novel compositions targeting protein tyrosine phosphatase sigma for nerve regeneration.
“OCTRI is proud to support these investigators and their important work furthering drug discovery at OHSU,” said David Ellison, M.D., director of OCTRI. “The Biomedical Innovation Program prioritizes commercialization outcomes to help develop technologies in ways that give them the best chance of successfully making it to the marketplace and improving human health. We are very excited to fund these projects for 2017, and look forward to working closely with the investigators.”
Detailed information on the Biomedical Innovation Program can be found on the OCTRI website.